PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single center, single-arm clinical trial in 20 patients with non-small
cell lung cancer (NSCLC) undergoing PD-1/PD-L1-directed therapy. This research is being done
to find out if the radioactive compound called [18F]F-AraG is a helpful imaging agent for
detecting changes in cancer's anti-tumor immune response (or activation of T-cell) levels for
non-small cell lung cancer (NSCLC) patients who will receive a cancer immunotherapy regimen
(immunotherapy works by encouraging the body's own immune system to attack the cancer cells).
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins